Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
FURESTEM-OA Kit Inj. Clinical Status and Open IR Articles
26
2024.01
Kangstem Biotech has begun imaging evaluation of the low-dose arm of its Phase 1 clinical trial for osteoarthritis.
Kangstem Biotech has begun imaging evaluation of the low-dose arm of its Phase 1 clinical trial for osteoarthritis. The company is conducting MRI-based imaging, the final phase of Phase 1, for patients in the low-dose group, and plans to complete the analysis of the results by the end of February through a third-party evaluator.
The osteoarthritis treatment ‘FURESTEM-OA Kit Inj.’ is a single intra-articular injection into the knee joint cavity that aims to provide fundamental treatment such as cartilage regeneration without surgery. In particular, the low and medium dose groups in the completed Phase 1 clinical trial demonstrated pain reduction and activity improvement through multiple endpoints and patients' daily lives. If this trend continues with the imaging evaluation for exploratory efficacy evaluation, we expect to achieve early technology export.
In addition, a corporate presentation of Kangstem Biotech will be held on the 31st to improve investors' understanding. Through this presentation, we will announce the status and future schedule of major clinical trials currently underway, including the schedule of interim checks and imaging evaluations for the low- and medium-dose groups of Purestem-OA Kitju, the timing of dosing for the high-dose group, and the timing of the results of the Phase 3 clinical trial of Purestem-Adju for the treatment of atopy.
The presentation will be held on January 31 at 3:00 p.m. in Ruby Hall on the second floor of the Conference Center at the Jeonnam Convention Center for individual investors, institutional investors, and those in the financial investment industry.